Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride (Q34011162)

30 July 2017

Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride (English)

1 reference

30 July 2017

0 references

0 references

1 reference

12

Anissa Abi-Dargham

1 reference

30 July 2017

Lawrence S Kegeles

1

1 reference

30 July 2017

Mark Slifstein

2

1 reference

30 July 2017

W Gordon Frankle

3

1 reference

30 July 2017

Xiaoyan Xu

4

1 reference

30 July 2017

Elizabeth Hackett

5

1 reference

30 July 2017

Sung-A Bae

6

1 reference

30 July 2017

Robyn Gonzales

7

1 reference

30 July 2017

Jong-Hoon Kim

8

1 reference

30 July 2017

Beatriz Alvarez

9

1 reference

30 July 2017

Roberto Gil

10

1 reference

30 July 2017

Marc Laruelle

11

1 reference

30 July 2017

language of work or name

English

0 references

publication date

16 April 2008

1 reference

30 July 2017

Neuropsychopharmacology

1 reference

30 July 2017

33

1 reference

30 July 2017

13

1 reference

30 July 2017

3111-3125

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2008.33

30 July 2017

0 references

cites work

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Statistical parametric maps in functional imaging: A general linear approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Consensus nomenclature for in vivo imaging of reversibly binding radioligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Agonist-receptor efficacy. II. Agonist trafficking of receptor signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Functional selectivity through protean and biased agonism: who steers the ship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

GPCR functional selectivity has therapeutic impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy--a simulation study based on experimental data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Limbic selectivity of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

The principal features and mechanisms of dopamine modulation in the prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

Evoked extracellular dopamine in vivo in the medial prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

D2-family receptor distribution in human postmortem tissue: an autoradiographic study

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

Simplified reference tissue model for PET receptor studies.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

MRI-PET registration with automated algorithm

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.33

7 January 2021

Identifiers

DOI

10.1038/NPP.2008.33

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference